Does the treatment of COVID-19 include tocilizumab?

Tocilizumab (tocilizumab) is an immunoglobulinIgG1 subtype recombinant humanized interleukin 6 (il-6) receptor monoclonal antibody. It controls the amount of virus replication in the human body by imitating the effect of natural antibodies of the immune system. Tocilizumab is the first monoclonal antibody approved by the FDA for the treatment of severe COVID-19 patients. Tocilizumab injection is recommended in the domestically issued "Novel Coronavirus Pneumonia Diagnosis and Treatment Plan"(Trial Ninth Edition) and can be used for severe and critical patients with laboratory testing elevated IL-6 levels. A guideline recommends the combination of multiple treatments for COVID-19 pneumonia for cancer patients, for example, containing IL-6 inhibitors such as tocilizumab.